|
FY2018
12 months to Dec 31, 2018
|
FY2017
12 months to Dec 31, 2017
|
FY2016
12 months to Dec 31, 2016
|
FY2015
12 months to Dec 31, 2015
|
FY2014
12 months to Dec 31, 2014
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Costs of processing and distribution | |||||
| Gross profit | |||||
| Expenses: | |||||
| Marketing, general and administrative | |||||
| Research and development | |||||
| Severance and restructuring costs | |||||
| Strategic review costs | |||||
| Executive transition costs | |||||
| Contested proxy expenses | |||||
| Asset impairment and abandonments | |||||
| Acquisition expenses | |||||
| Acquisition and integration expenses | |||||
| Cardiothoracic closure business divestiture contingency consideration | |||||
| Gain on cardiothoracic closure business divestiture | |||||
| Total operating expenses | |||||
| Operating (loss) income | |||||
| Other (expense) income: | |||||
| Interest expense | |||||
| Interest income | |||||
| Loss on extinguishment of debt | |||||
| Foreign exchange (loss) gain | |||||
| Total other expense - net | |||||
| (Loss) income before income tax (provision) benefit | |||||
| Income tax benefit (provision) | |||||
| Net (loss) income | |||||
| Convertible preferred dividend | |||||
| Net (loss) income applicable to common shares | |||||
| Other comprehensive (loss) income: | |||||
| Unrealized foreign currency translation loss | |||||
| Comprehensive (loss) income | |||||
| Net (loss) income per common share - basic | |||||
| Net (loss) income per common share - diluted | |||||
| Weighted average shares outstanding - basic | |||||
| Weighted average shares outstanding - diluted | |||||
Loading...